SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
04
11
2022
accepted:
28
06
2023
medline:
17
8
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. After a dose-escalated phase 1 safety study, 90 participants were randomized to receive CoV-2-ST+SoC (n = 60) or SoC only (n = 30). The co-primary objectives of the study were the composite of time to recovery and 30-d recovery rate and the in vivo expansion of CoV-2-STs in patients receiving CoV-2-ST+SoC over SoC. The key secondary objective was survival on day 60. CoV-2-ST+SoC treatment was safe and well tolerated. The study met the primary composite endpoint (CoV-2-ST+SoC versus SoC: recovery rate 65% versus 38%, P = 0.017; median recovery time 11 d versus not reached, P = 0.052, respectively; rate ratio for recovery 1.71 (95% confidence interval 1.03-2.83, P = 0.036)) and the co-primary objective of significant CoV-2-ST expansion compared to SοC (CoV-2-ST+SoC versus SoC, P = 0.047). Overall, in hospitalized patients with severe COVID-19, adoptive immunotherapy with CoV-2-STs was feasible and safe. Larger trials are needed to strengthen the preliminary evidence of clinical benefit in severe COVID-19. EudraCT identifier: 2021-001022-22 .
Identifiants
pubmed: 37460756
doi: 10.1038/s41591-023-02480-8
pii: 10.1038/s41591-023-02480-8
doi:
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2019-2029Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).
pubmed: 35172054
doi: 10.1056/NEJMoa2118542
Owen, D. R. et al. An oral SARS-CoV-2 M
pubmed: 34726479
doi: 10.1126/science.abl4784
Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).
pubmed: 34914868
doi: 10.1056/NEJMoa2116044
Gordon, A. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
pubmed: 33631065
doi: 10.1056/NEJMoa2100433
Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).
pubmed: 32678530
doi: 10.1056/NEJMoa2021436
Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 383, 1813–1826 (2020).
pubmed: 32445440
doi: 10.1056/NEJMoa2007764
Papadopoulou, A. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl. Med. 6, 242ra83 (2014).
pubmed: 24964991
pmcid: 4181611
doi: 10.1126/scitranslmed.3008825
Tzannou, I. et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein–Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J. Clin. Oncol. 35, 3547–3557 (2017).
pubmed: 28783452
pmcid: 5662844
doi: 10.1200/JCO.2017.73.0655
O’Reilly, R. J., Prockop, S., Hasan, A. N., Koehne, G. & Doubrovina, E. Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections. Bone Marrow Transplant. 51, 1163–1172 (2016).
pubmed: 27042851
pmcid: 5356365
doi: 10.1038/bmt.2016.17
Jiang, W. et al. Pathogen-specific T cells beyond CMV, EBV and adenovirus. Curr. Hematol. Malig. Rep. 14, 247–260 (2019).
pubmed: 31228095
doi: 10.1007/s11899-019-00521-z
Kaeuferle, T., Krauss, R., Blaeschke, F., Willier, S. & Feuchtinger, T. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J. Hematol. Oncol. 12, 13 (2019).
Baugh, K. A., Tzannou, I. & Leen, A. M. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Curr. Opin. Infect. Dis. 31, 292–300 (2018).
pubmed: 29750672
pmcid: 7896200
doi: 10.1097/QCO.0000000000000456
Papadopoulou, A., Alvanou, M., Karavalakis, G., Tzannou, I. & Yannaki, E. Pathogen-specific T cells: targeting old enemies and new invaders in transplantation and beyond. Hemasphere 7, e809 (2023).
pubmed: 36698615
pmcid: 9831191
doi: 10.1097/HS9.0000000000000809
Kim, N. et al. Off-the-shelf partial HLA matching SARS-CoV-2 antigen specific T cell therapy: a new possibility for COVID-19 treatment. Front. Immunol. 12, 5562 (2021).
doi: 10.3389/fimmu.2021.751869
Keller, M. D. et al. SARS-CoV-2 specific T-cells are rapidly expanded for therapeutic use and target conserved regions of membrane protein. Blood 136, 2905–2917 (2020).
pubmed: 33331927
pmcid: 7746091
doi: 10.1182/blood.2020008488
Kedzierska, K. & Thomas, P. G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep. Med. 3, 100562 (2022).
pubmed: 35474748
pmcid: 8872824
doi: 10.1016/j.xcrm.2022.100562
Ferreras, C. et al. SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy. Front. Cell Dev. Biol. 9, 293 (2021).
doi: 10.3389/fcell.2021.620730
Cooper, R. S. et al. Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19. Front. Immunol. 11, 598402 (2021).
Leung, W. et al. Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells. Adv. Cell Gene Ther. 3, e101 (2020).
Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186–193 (2022).
pubmed: 35105982
doi: 10.1038/s41590-021-01122-w
Papayanni, P.-G. et al. Vaccinated and convalescent donor–derived severe acute respiratory syndrome coronavirus 2-specific T cells as adoptive immunotherapy for high-risk coronavirus disease 2019 patients. Clin. Infect. Dis. 73, 2073–2082 (2021).
pubmed: 33905481
pmcid: 8135332
doi: 10.1093/cid/ciab371
Anderson, B. E. et al. Memory CD4
pubmed: 12840064
pmcid: 162285
doi: 10.1172/JCI17601
Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, 698–702 (2010).
doi: 10.1136/bmj.c332
Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233–1244 (2020).
pubmed: 33075298
pmcid: 7567529
doi: 10.1016/S2213-2600(20)30404-5
Narni-Mancinelli, E. & Vivier, E. Clues that natural killer cells help to control COVID. Nature 600, 226–227 (2021).
pubmed: 34697480
doi: 10.1038/d41586-021-02778-y
Wei, R. et al. A landscape study on COVID-19 immunity at the single-cell level. Front. Immunol. 13, 918383 (2022).
pubmed: 35911765
pmcid: 9334848
doi: 10.3389/fimmu.2022.918383
Barouch, D. H. Covid-19 vaccines—immunity, variants, boosters. N. Engl. J. Med. 387, 1011–1020 (2022).
pubmed: 36044620
doi: 10.1056/NEJMra2206573
Antunez Muiños, P. J. et al. The COVID-19 lab score: an accurate dynamic tool to predict in-hospital outcomes in COVID-19 patients. Sci. Rep. 11, 9361 (2021).
pubmed: 33931677
pmcid: 8087839
doi: 10.1038/s41598-021-88679-6
Huang, I., Pranata, R., Lim, M. A., Oehadian, A. & Alisjahbana, B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther. Adv. Respir. Dis. 14, 1753466620937175 (2020).
Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333–2344 (2020).
pubmed: 33085857
doi: 10.1056/NEJMoa2028836
Hermine, O. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 32–40 (2021).
pubmed: 33080017
doi: 10.1001/jamainternmed.2020.6820
Cao, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787–1799 (2020).
pubmed: 32187464
doi: 10.1056/NEJMoa2001282
Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020).
pubmed: 32217835
pmcid: 7190990
doi: 10.1172/JCI137244
Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 864–877 (2020).
pubmed: 32791036
pmcid: 7402670
doi: 10.1016/j.immuni.2020.07.026
Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481 (2020).
pubmed: 32105632
pmcid: 7102538
doi: 10.1016/S2213-2600(20)30079-5
Le Bert, N. et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 218, e20202617 (2021).
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996 (2020).
pubmed: 33010815
pmcid: 7494270
doi: 10.1016/j.cell.2020.09.038
Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158–168 (2020).
pubmed: 32979941
pmcid: 7427556
doi: 10.1016/j.cell.2020.08.017
Tzannou, I. et al. Immunologic profiling of human metapneumovirus for the development of targeted immunotherapy. J. Infect. Dis. 216, 678–687 (2017).
pubmed: 28934427
doi: 10.1093/infdis/jix358
McLaughlin, L. P. et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T-lymphocytes. Cytotherapy 18, 1515 (2016).
pubmed: 27692559
pmcid: 5096976
doi: 10.1016/j.jcyt.2016.08.010
McKinstry, K. K. et al. Memory CD4
pubmed: 22820287
pmcid: 3408751
doi: 10.1172/JCI63689
Wilkinson, T. M. et al. Preexisting influenza-specific CD4
pubmed: 22286307
doi: 10.1038/nm.2612
Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4
pubmed: 22266691
pmcid: 3764486
doi: 10.1038/nri3152
Bollard, C. M. & Heslop, H. E. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127, 3331–3340 (2016).
pubmed: 27207801
pmcid: 4929925
doi: 10.1182/blood-2016-01-628982
Vasileiou, S. et al. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica 108, 1840–1850 (2023).
pubmed: 36373249
doi: 10.3324/haematol.2022.281946
Cruz, C. R. et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 12, 743–749 (2010).
pubmed: 20429793
pmcid: 2914831
doi: 10.3109/14653241003709686
Papadopoulou, A. et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol. Ther. 22, 1134–1138 (2014).
pubmed: 24651135
pmcid: 4048900
doi: 10.1038/mt.2014.48
Bates, T. A. et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci. Immunol. 7, eabn8014 (2022).
Rodda, L. B. et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell 185, 1588–1601 (2022).
pubmed: 35413241
pmcid: 8926873
doi: 10.1016/j.cell.2022.03.018
Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113–5123 (2013).
pubmed: 23610374
pmcid: 3695359
doi: 10.1182/blood-2013-02-486324
Service, R. F. Bad news for Paxlovid? Resistance may be coming. Science 377, 138–139 (2022).
pubmed: 35857562
doi: 10.1126/science.add8037
Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558–564 (2023).
Rubin, R. From positive to negative to positive again—the mystery of why COVID-19 rebounds in some patients who take Paxlovid. JAMA 327, 2380–2382 (2022).
pubmed: 35675094
doi: 10.1001/jama.2022.9925
US Food and Drug Administration. Clinical Considerations for Therapeutic Cancer Vaccines: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-therapeutic-cancer-vaccines (2011).
Papadopoulou, A. et al. Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host. Bone Marrow Transpl. 54, 1963–1972 (2019).
doi: 10.1038/s41409-019-0501-9
Stallard, N. Optimal sample sizes for phase II clinical trials and pilot studies. Stat. Med. 31, 1031–1042 (2012).
pubmed: 22052407
doi: 10.1002/sim.4357